A clinical trial comparing Armour Thyroid (NDT) and Levothyroxine (LT4) is now recruiting patients in the United States. The sponsor of the study is Allergan, the makers of Armour Thyroid in the United States. They hope to recruit 220 patients at multiple locations listed on the clinical trial website. In this post, I provide what … Continue reading New clinical trial of Armour Thyroid is recruiting U.S. patients
At this time of year, many nonprofit organizations focus on the relief of poverty and hunger. But humans can also suffer T3 hormone poverty and hunger. We can't be truly healthy without "enough" T3 in our bloodstream, our tissues, organs and cells. We can't be healthy with "too much" T3 activity in cells, either. Well-regulated … Continue reading Our wish: May you be blessed with T3 sufficiency
We're trying a new strategy to crowdsource data on Canadian thyroid patients' access to thyroid laboratory testing. For a limited time, we are test-driving an anonymous survey with a real-time report that displays up to date statistics and results. Take the survey Here's the link to the Canadian Thyroid Testing Tips & Challenges survey page. … Continue reading Survey: Canadian Thyroid Testing Tips & Challenges
A fundamental principle energizes any group of thyroid patients to try to improve thyroid therapy: Some thyroid-disabled people have suffered a lot and have won partial victories in their own thyroid therapy. Now that they are on a therapy that is better than before, even if it might be far from perfect yet, they can … Continue reading Healthier thyroid warriors: Our fight is not over.
This final section of my paraphrase of Hoermann et al's landmark 2016 article articulates the shift from the limited, older TSH-T4 paradigm to the new paradigm that includes T3 hormone. Interrelational Measures and Emerging New Concepts of Thyroid Homeostasis [Paraphrase begins] TSH can play a useful role in screening patients who do not have any … Continue reading Relational Stability, part 4: The new thyroid paradigm